Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Key Stats

• Today's Range: $4.80 to $5.11
• 50-Day Range: $3.67 to $4.92
• 52-Week Range: $1.45 to $12.37
• Volume: 519,073 shs
• Average Volume: 392,470 shs
• Market Capitalization: $264.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 594th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexeo Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexeo Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.93% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 1.35%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

22.93% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 1.35%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.01

News Sentiment

Lexeo Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for LXEO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,696.00 in company stock.

Percentage Held by Insiders

Only 5.30% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LXEO Stock Analysis - Frequently Asked Questions

How have LXEO shares performed this year?

Lexeo Therapeutics' stock was trading at $6.58 at the beginning of 2025. Since then, LXEO stock has decreased by 25.5% and is now trading at $4.90.

How were Lexeo Therapeutics' earnings last quarter?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04.

When did Lexeo Therapeutics IPO?

Lexeo Therapeutics (LXEO) raised $100 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share.

Who are Lexeo Therapeutics' major shareholders?

Lexeo Therapeutics' top institutional investors include Frazier Life Sciences Management L.P. (13.33%), Balyasny Asset Management L.P. (12.08%), Affinity Asset Advisors LLC (10.81%) and Vestal Point Capital LP (9.72%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Eric Adler, Jose Manuel Otero and Tai Sandi See.
View institutional ownership trends.

How do I buy shares of Lexeo Therapeutics?

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexeo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $15.33
• High Price Target: $20.00
• Low Price Target: $9.00
• Potential Upside/Downside: +212.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$98.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.65%
• Return on Assets: -73.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.43
• Quick Ratio: 3.42

Sales & Book Value

• Annual Sales: $650 thousand
• Price / Sales: 407.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.56 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 54,000,000
• Free Float: 51,139,000
• Market Cap: $264.60 million
• Optionable: Not Optionable
• Beta: 1.36